[{"id":5,"entrez_name":"ALK","entrez_id":238,"name":"EML4-ALK","description":"The EML4-ALK fusion has been seen in non-small cell lung cancer, and appears to be an alternative mechanism for ALK activation. Cells with this fusion have been shown to be sensitive to the ALK inhibitor crizotinib.","evidence_items":[{"id":8,"text":"In patients with non-small cell lung cancer harboring the EML4-ALK fusion, treatment with crizotinib has shown to be effective in acheiving stable disease.","disease":"Non-small Cell Lung Carcinoma","doid":"3908","citation":"Choi et al., 2010, N. Engl. J. Med.","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/20979473","pubmed_id":"20979473","drugs":[{"id":6,"name":"Crizotinib","pubchem_id":null}],"rating":4,"evidence_level":"B","evidence_type":"Predictive","clinical_significance":"Sensitivity","evidence_direction":"Supports","variant_hgvs":"N/A","variant_origin":"Somatic"}],"variant_groups":[{"id":2,"name":"ALK Fusions","description":"ALK fusion positive non-small cell lung cancer (NSCLC) is treated as its own subset of NSCLC. Many ALK fusions that have been seen as recurrent in cancer serve to increase the activity of the ALK oncogene relative to normal cells. While EML4 is the most common fusion partner, other 5' partners have been observed. The EML4-ALK fusion has shown sensitivity to targeted tyrosine kinase inhibitors such as crizotinib. "}]},{"id":6,"entrez_name":"ALK","entrez_id":238,"name":"EML4-ALK C1156Y","description":"In patients with non-small cell lung cancer exhibiting EML4-ALK fusion, this variant has been shown to confer resistance to crizotinib.","evidence_items":[{"id":9,"text":"In patients with non-small cell lung cancer harboring EML4-ALK fusion, the C1156Y variant has been shown to confer resistance to crizotinib.","disease":"Non-small Cell Lung Carcinoma","doid":"3908","citation":"Choi et al., 2010, N. Engl. J. Med.","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/20979473","pubmed_id":"20979473","drugs":[{"id":6,"name":"Crizotinib","pubchem_id":null}],"rating":4,"evidence_level":"B","evidence_type":"Predictive","clinical_significance":"Resistance or Non-Response","evidence_direction":"Supports","variant_hgvs":"N/A","variant_origin":"Somatic"}],"variant_groups":[{"id":2,"name":"ALK Fusions","description":"ALK fusion positive non-small cell lung cancer (NSCLC) is treated as its own subset of NSCLC. Many ALK fusions that have been seen as recurrent in cancer serve to increase the activity of the ALK oncogene relative to normal cells. While EML4 is the most common fusion partner, other 5' partners have been observed. The EML4-ALK fusion has shown sensitivity to targeted tyrosine kinase inhibitors such as crizotinib. "},{"id":3,"name":"Crizotinib Resistance","description":"The ALK oncogene has long been considered a driving factor in non-small cell lung cancer (NSCLC). The targeted tyrosine kinase inhibitor criztonib has shown to be effective in ALK-mutant NSCLC. However, in patients that have shown acquired resistance to crizotinib, missense mutations in the tyrosine kinase domain have shown to drive this resistance. "}]},{"id":7,"entrez_name":"ALK","entrez_id":238,"name":"EML4-ALK L1196M","description":"In patients with non-small cell lung cancer exhibiting EML4-ALK fusion, this variant has been shown to confer resistance to crizotinib.","evidence_items":[{"id":11,"text":"In patients with non-small cell lung cancer harboring EML4-ALK fusion, the L1196M variant has been shown to confer resistance to crizotinib.","disease":"Non-small Cell Lung Carcinoma","doid":"3908","citation":"Choi et al., 2010, N. Engl. J. Med.","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/20979473","pubmed_id":"20979473","drugs":[{"id":6,"name":"Crizotinib","pubchem_id":null}],"rating":4,"evidence_level":"B","evidence_type":"Predictive","clinical_significance":"Resistance or Non-Response","evidence_direction":"Supports","variant_hgvs":"N/A","variant_origin":"Somatic"},{"id":10,"text":"CH5424802 treatment resulted in significant tumor regression in xenograft models produced from Ba/F3 cells expressing EML4-ALK or AML4-ALK with the L1196M mutation","disease":"Non-small Cell Lung Carcinoma","doid":"3908","citation":"Sakamoto et al., 2011, Cancer Cell","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/21575866","pubmed_id":"21575866","drugs":[{"id":7,"name":"CH5424802","pubchem_id":null}],"rating":3,"evidence_level":"C","evidence_type":"Predictive","clinical_significance":"Sensitivity","evidence_direction":"Supports","variant_hgvs":"N/A","variant_origin":"Somatic"}],"variant_groups":[{"id":2,"name":"ALK Fusions","description":"ALK fusion positive non-small cell lung cancer (NSCLC) is treated as its own subset of NSCLC. Many ALK fusions that have been seen as recurrent in cancer serve to increase the activity of the ALK oncogene relative to normal cells. While EML4 is the most common fusion partner, other 5' partners have been observed. The EML4-ALK fusion has shown sensitivity to targeted tyrosine kinase inhibitors such as crizotinib. "},{"id":3,"name":"Crizotinib Resistance","description":"The ALK oncogene has long been considered a driving factor in non-small cell lung cancer (NSCLC). The targeted tyrosine kinase inhibitor criztonib has shown to be effective in ALK-mutant NSCLC. However, in patients that have shown acquired resistance to crizotinib, missense mutations in the tyrosine kinase domain have shown to drive this resistance. "}]},{"id":8,"entrez_name":"ALK","entrez_id":238,"name":"F1174L","description":"ALK F1174L has been observed as recurrent in neuroblastoma, non-small cell lung cancer (NSCLC), and other cancer types. Neuroblastoma cells containing this mutation have shown resistance to low doses of criztonib. However, increased dosage can overcome this resistance in cell lines studies. TAE684 has also proven effective in both NSCLC and neuroblastoma F1174L containing cells.","evidence_items":[{"id":17,"text":"Ba/F3 cells expressing the EML4-ALK fusion containing an F1174L mutation were more resistant to crizotinib treatment than Ba/F3 cells expressing EML4-ALK without this mutation.","disease":"Non-small Cell Lung Carcinoma","doid":"3908","citation":"Sasaki et al., 2010, Cancer Res.","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/21030459","pubmed_id":"21030459","drugs":[{"id":6,"name":"Crizotinib","pubchem_id":null}],"rating":3,"evidence_level":"C","evidence_type":"Predictive","clinical_significance":"Resistance or Non-Response","evidence_direction":"Supports","variant_hgvs":"2:29443695-29443695 (G-\u003eT)","variant_origin":"Somatic"},{"id":16,"text":"SH-SY5Y and Kelly cells with mutant ALK (F1174L) and Ba/F3 cells overexpressing ALK harboring the F1174L mutation are sensitive to TAE684-mediated growth inhibition","disease":"Neuroblastoma","doid":"769","citation":"George et al., 2008, Nature","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/18923525","pubmed_id":"18923525","drugs":[{"id":8,"name":"TAE684","pubchem_id":null}],"rating":4,"evidence_level":"C","evidence_type":"Predictive","clinical_significance":"Sensitivity","evidence_direction":"Supports","variant_hgvs":"2:29443695-29443695 (G-\u003eT)","variant_origin":"Somatic"},{"id":15,"text":"High levels of crizotinib can overcome drug resistance of Ba/F3 cells expressing the EML4-ALK fusion containing the F1174L mutation.","disease":"Neuroblastoma","doid":"769","citation":"Heuckmann et al., 2011, Clin. Cancer Res.","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/21948233","pubmed_id":"21948233","drugs":[{"id":6,"name":"Crizotinib","pubchem_id":null}],"rating":3,"evidence_level":"C","evidence_type":"Predictive","clinical_significance":"Sensitivity","evidence_direction":"Supports","variant_hgvs":"2:29443695-29443695 (G-\u003eT)","variant_origin":"Somatic"},{"id":14,"text":"Cells lines expressing ALK harboring the F1174L mutation are less sensitive to growth inhibition by crizotinib than cells expressing the R1275Q mutation.","disease":"Neuroblastoma","doid":"769","citation":"Bresler et al., 2011, Sci Transl Med","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/22072639","pubmed_id":"22072639","drugs":[{"id":6,"name":"Crizotinib","pubchem_id":null}],"rating":3,"evidence_level":"C","evidence_type":"Predictive","clinical_significance":"Resistance or Non-Response","evidence_direction":"Supports","variant_hgvs":"2:29443695-29443695 (G-\u003eT)","variant_origin":"Somatic"},{"id":13,"text":"CH5424802 is effective in inhibiting the activity of the F1174L ALK mutant in a kinase activity assay and proliferation assay using neuroblastoma KELLY cells.","disease":"Neuroblastoma","doid":"769","citation":"Sakamoto et al., 2011, Cancer Cell","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/21575866","pubmed_id":"21575866","drugs":[{"id":7,"name":"CH5424802","pubchem_id":null}],"rating":3,"evidence_level":"C","evidence_type":"Predictive","clinical_significance":"Sensitivity","evidence_direction":"Supports","variant_hgvs":"2:29443695-29443695 (G-\u003eT)","variant_origin":"Somatic"},{"id":12,"text":"Ba/F3 cells expressing the RANBP2-ALK fusion containing an F1174L mutation were more resistant to crizotinib treatment than Ba/F3 cells expressing RANBP2-ALK without this mutation.","disease":"Inflammatory Myofibroblastic Tumor","doid":"0050905","citation":"Sasaki et al., 2010, Cancer Res.","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/21030459","pubmed_id":"21030459","drugs":[{"id":6,"name":"Crizotinib","pubchem_id":null}],"rating":3,"evidence_level":"C","evidence_type":"Predictive","clinical_significance":"Resistance or Non-Response","evidence_direction":"Supports","variant_hgvs":"2:29443695-29443695 (G-\u003eT)","variant_origin":"Somatic"}],"variant_groups":[{"id":3,"name":"Crizotinib Resistance","description":"The ALK oncogene has long been considered a driving factor in non-small cell lung cancer (NSCLC). The targeted tyrosine kinase inhibitor criztonib has shown to be effective in ALK-mutant NSCLC. However, in patients that have shown acquired resistance to crizotinib, missense mutations in the tyrosine kinase domain have shown to drive this resistance. "}]},{"id":9,"entrez_name":"ALK","entrez_id":238,"name":"R1275Q","description":"ALK R1275Q has been observed as a recurrent mutation in  neuroblastoma, non-small cell lung cancer (NSCLC), as well as other cancer types. Neuroblastoma cells with this mutation have shown sensitivity to the ALK-inhibitor TAE684. This, and the geldanamycin deriviative 17-DMAG, has been shown to be effective in NSCLC cell lines.","evidence_items":[{"id":20,"text":"The SMS-KCNR cell line harboring the R1275Q mutation was resistant to TAE684.","disease":"Neuroblastoma","doid":"769","citation":"George et al., 2008, Nature","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/18923525","pubmed_id":"18923525","drugs":[{"id":8,"name":"TAE684","pubchem_id":null}],"rating":3,"evidence_level":"C","evidence_type":"Predictive","clinical_significance":"Resistance or Non-Response","evidence_direction":"Supports","variant_hgvs":"2:29432664-29432664 (C-\u003eT)","variant_origin":"Somatic"},{"id":19,"text":"TAE684 inhibits growth of Ba/F3 cells expressing ALK mutations; however, cells with the R1275Q mutation were inhibited at a higher IC50 than those expressing F1174L.","disease":"Neuroblastoma","doid":"769","citation":"George et al., 2008, Nature","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/18923525","pubmed_id":"18923525","drugs":[{"id":8,"name":"TAE684","pubchem_id":null}],"rating":3,"evidence_level":"C","evidence_type":"Predictive","clinical_significance":"Sensitivity","evidence_direction":"Supports","variant_hgvs":"2:29432664-29432664 (C-\u003eT)","variant_origin":"Somatic"},{"id":18,"text":"Cells lines expressing ALK harboring the F1174L mutation are less sensitive to growth inhibition by crizotinib than cells expressing the R1275Q mutation","disease":"Neuroblastoma","doid":"769","citation":"Bresler et al., 2011, Sci Transl Med","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/22072639","pubmed_id":"22072639","drugs":[{"id":6,"name":"Crizotinib","pubchem_id":null}],"rating":3,"evidence_level":"C","evidence_type":"Predictive","clinical_significance":"Sensitivity","evidence_direction":"Supports","variant_hgvs":"2:29432664-29432664 (C-\u003eT)","variant_origin":"Somatic"}],"variant_groups":[]}]